Revolution Medicines Drugged a Target Scientists Called “Undruggable” for Decades. Buy the Stock Hand Over Fist?

The Motley Fool · 21h ago

Key Points

  • Revolution Medicines’ Rasonque performed extremely well in Phase 3 studies.

  • The drug generated $198 million in five weeks, marking the strongest launch of an oncology drug on record.

  • Revolution Medicines’ prospects arguably justify its valuation.

Revolution Medicines (NASDAQ:RVMD) is living up to its name. Earlier this year, the biotech company earned approval for Rasonque, a medicine for pancreatic cancer that targets one of the main genetic drivers of the disease, the first of its kind to do so. Rasonque's approval was a major milestone, and Revolution Medicines has already been rewarded for it. Shares are up 100% this year. Is there any upside left for the drugmaker?

Scientists in a lab review a sample.

Image source: Getty Images.

Missed AI’s "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our analysts, we’re only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »

A little more on Rasonque

Many new drugs are tested against a placebo in Phase 3 clinical trials. Being pitted against the standard of care is a much tougher bar to clear. Yet, that's exactly what Rasonque did. In a Phase 3 study, investigators pitted the medicine against cytotoxic chemotherapy, the current standard of care, in patients with previously treated metastatic pancreatic cancer.

Rasonque won hands down. It led to a median overall survival of 13.2 months, compared with 6.7 months with cytotoxic chemotherapy. Why is Rasonque so effective? It has a new mechanism of action that targets RAS-addicted cancers (RAS is a protein implicated in the rapid growth of some cancers), which have historically been difficult to treat.

According to Revolution Medicines, RAS-addicted cancers account for between 20% and 30% of all human cancers. So, the company could earn approval for Rasonque and some other candidates in its pipeline across various indications. Revolution Medicines is running eight Phase 3 clinical trials, including several for two other investigational medicines, zoldonrasib and elironrasib. Provided Rasonque experiences a strong commercial ramp-up, and the company makes significant clinical progress over the next few years, Revolution Medicines' shares could maintain strong momentum.

Are sales projections high enough to justify the valuation?

Rasonque earned approval in late August. Yet, in the third quarter, Revolution Medicines generated $198 million in revenue from the medicine, in the roughly five weeks it was on the market before the quarter ended. It was prescribed to more than 5,000 unique patients in the U.S. Some analysts are calling it the strongest launch in the history of the oncology drug market, which is typically dominated by pharmaceutical leaders.

That's impressive, and it highlights the massive opportunity Revolution Medicines is tapping into. That helps put Revolution Medicines' valuation in perspective. The company's current market cap is $34.8 billion, which is quite high for a biotech company that just launched its first product. However, note that Revolution Medicines' stock has declined about 29% since Rasonque's approval, even as the company's initial launch of the drug has crushed expectations.

If anything, Revolution Medicines' third-quarter results show that the market cap it had several months ago, which hovered around $50 billion, may not have been unfounded after all. Consider that some analysts now expect the company to generate $3 billion in revenue next year. Based on this projection, Revolution Medicines is trading at 11.6x estimated 2027 sales.

That's not completely unreasonable for a biotech of this size with a transformative new treatment that could become the standard of care across several oncology indications, the largest market in the pharmaceutical industry. Of course, there is some uncertainty to consider. Revolution Medicines might not make as much next year as some analysts expect.

There is also the possibility of clinical and regulatory setbacks. Even so, Rasonque's trajectory so far, and the fact that clinical progress has been strong -- and Revolution Medicines has a robust pipeline -- make a strong case for the stock. That's especially true since Rasonque recently earned approval in Europe.

And Revolution Medicines will also seek approvals in other countries, including Japan. In my view, the opportunity in the U.S. alone, where Revolution Medicines estimates that about 55,000 new cases of metastatic pancreatic cancer occur annually, justifies its current valuation. So, the stock is worth buying right now and holding onto for at least the next five years.

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.